“How I treat” autoimmune diseases: State of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis

Autoimmunity Reviews

Volumn 16, Issue 10, 2017, Pages 995-998

  Roccatello, Dario ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

Adult onset Still's disease; ANCA; ANCA vasculitis; Autoimmune diseases; Eosinophilic Granulomatosis with Polyangiitis; Granulomatosis with Polyangiitis; Idiopathic inflammatory myopathies; Juvenile idiopathic arthritis; Microscopic Polyangiitis; Rituximab; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RITUXIMAB;

ALGORITHM; ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; CLINICAL PRACTICE; DISEASE SEVERITY; EDITORIAL; HUMAN; MICROSCOPIC POLYANGIITIS; PRACTICE GUIDELINE; RELAPSE; REMISSION; RHEUMATIC DISEASE; WEGENER GRANULOMATOSIS; IMMUNOLOGY; VASCULITIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASES; HUMANS; RHEUMATIC DISEASES; VASCULITIS;

EID: 85028315848     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.07.015     Document Type: Editorial

References (25)

1. Cimaz, R., Marino, A., Alberto Martini, A., How I treat juvenile idiopathic arthritis: a state of the art review. Autoimmun Rev 16 (2017), 1008–1015.
2. Rossi, D., Zanatta, E., Marson, P., Sciascia, S., Polito, P., Roccatello, D., et al. How I treat patients with systemic sclerosis in clinical practice. Autoimmun Rev 16 (2017), 1024–1028.
3. Cavagna, L., Monti, S., Caporali, R., Gatto, M., Iaccarino, L., Doria, A., How I treat idiopathic patients with inflammatory myopathies in the clinical practice. Autoimmun Rev 16 (2017), 999–1007.
4. Govoni, M., Bortoluzzi, A., Rossi, D., Modena, V., How I treat patients with adult onset Still's disease in clinical practice. Autoimmun Rev 16 (2017), 1016–1023.
5. Kronbichler, A., Windpessl, M., Pieringer, H., Jayne, D.R.W., Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev 16 (2017), 633–643.
6. Cottin, V., Bel, E., Bottero, P., Dalhoff, K., Humbert, M., Lazor, R., et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev 16 (2017), 1–9.
7. Jarrot, P.A., Kaplanski, G., Pathogenesis of ANCA-associated vasculitis: an update. Autoimmun Rev 15 (2016), 704–713.
8. Csernok, E., Damoiseaux, J., Rasmussen, N., Hellmich, B., van Paassen, P., Vermeersch, P., et al. Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Autoimmun Rev 15 (2016), 736–741.
9. Iannella, G., Greco, A., Granata, G., Manno, A., Pasquariello, B., Angeletti, D., et al. Granulomatosis with polyangiitis and facial palsy: literature review and insight in the autoimmune pathogenesis. Autoimmun Rev 15 (2016), 621–631.
10. Kallenberg, C.G.M., Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis 70:Suppl. 1 (2011), i59–63, 10.1136/ard.2010.138024.
11. Xie, G., Roshandel, D., Sherva, R., Monach, P.A., Lu, E.Y., Kung, T., et al. Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum 65 (2013), 2457–2468, 10.1002/art.38036.
12. Specks, U., Merkel, P.A., Seo, P., Spiera, R., Langford, C.A., Hoffman, G.S., et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369 (2013), 417–427, 10.1056/NEJMoa1213277.
13. Jones, R.B., Cohen Tervaert, J.W., Hauser, T., Luqmani, R., Morgan, M.D., Peh, C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363 (2010), 211–220, 10.1056/NEJMoa0909169.
14. Charles, P., Neel, A., Tieulie, N., Hot, A., Pugnet, G., Decaux, O., et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology 53 (2014), 532–539, 10.1093/rheumatology/ket381.
15. Roccatello, D., Sciascia, S., Rossi, D., Alpa, M., Naretto, C., Russo, A., et al. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol 34 (2011), 175–180, 10.1159/000329535.
16. Harper, L., Morgan, M.D., Walsh, M., Hoglund, P., Westman, K., Flossmann, O., et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71 (2012), 955–960, 10.1136/annrheumdis-2011-200477.
17. de Joode, A.A.E., Sanders, J.S.F., Smid, W.M., Stegeman, C.A., Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: single-center results of stepwise escalation of immunosuppression. J Clin Apher 29 (2014), 266–272, 10.1002/jca.21318.
18. Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J.W.C., Dadoniené, J., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003), 36–44, 10.1056/NEJMoa020286.
19. Springer, J., Nutter, B., Langford, C.A., Hoffman, G.S., Villa-Forte, A., Granulomatosis with polyangiitis (Wegener's). Medicine (Baltimore) 93 (2014), 82–90, 10.1097/MD.0000000000000020.
20. Cartin-Ceba, R., Golbin, J.M., Keogh, K.A., Peikert, T., Sánchez-Menéndez, M., Ytterberg, S.R., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 64 (2012), 3770–3778, 10.1002/art.34584.
21. Jones, R.B., Ferraro, A.J., Chaudhry, A.N., Brogan, P., Salama, A.D., Smith, K.G.C., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60 (2009), 2156–2168, 10.1002/art.24637.
22. Roubaud-Baudron, C., Pagnoux, C., Méaux-Ruault, N., Grasland, A., Zoulim, A., LE Guen, J., et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 39 (2012), 125–130, 10.3899/jrheum.110143.
23. Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaitre, O., Cohen, P., et al. Rituximab versus Azathioprine for maintenance in ANCA-associated vasculitis [abstract]. Arthritis Rheum, 2012, S706.
24. Roccatello, D., Sciascia, S., Rossi, D., Alpa, M., Naretto, C., Radin, M., et al. The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: a 10 years observation study. Oncotarget, 2017, 5, 10.18632/oncotarget.18120.
25. Roccatello, D., Sciascia, S., Baldovino, S., Rossi, D., Alpa, M., Naretto, C., et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-clinical response compared to literature and immunological re-assessment. Autoimmun Rev 14 (2015), 1123–1130.